A Pharmacogenomics study looked at individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype, who are are at an increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, researchers sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals.
Analysis of the two trials demonstrated a significant overall reduction in the composite end point in Hp 2-2 DM individuals with vitamin E. Lifelong administration of vitamin E to Hp 2-2 DM individuals in the population would increase their life expectancy by 3 years. A pharmacogenomic strategy of screening DM individuals for the Hp genotype and treating those with Hp 2-2 with vitamin E appears to be highly clinically effective.
Steve - nice to see vitamin E getting some love!
Friday, June 04, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment